JPRN-UMIN000002397已完成2 期
Phase II study of combination chemotherapy in treating pediatric patients with newly diagnosed intracranial germinoma - Combination chemotherapy in treating pediatric patients with intracranial germinoma
Japanese Pediatric Brain Tumor Consortium0 个研究点目标入组 50 人开始时间: 2009年8月28日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 3years-old 至 25years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Has double cancer. Has cardiac disease for which treatment is necessary.
研究者
相似试验
已完成
2 期
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22
已完成
1 期
Phase 1/2 study of triple combination chemotherapy with Carboplatin, nab-Paclitaxel, and Bevacizumab for chemotherapy-naïve stageIIIB/IV non- squamous non-small-cell lung cancer (TORG1424/OLCSG1402)Advanced stage IIIB/IV non-squamous non-small cell lung cancerJPRN-UMIN000014560Thoracic Oncology Research Group55
未知
2 期
A phase II study of combination chemotherapy of oral tegafur/uracil, leucovorin and bevacizumab for patients not appropriate for intensive therapy with unresectable or recurrent colorectal cancerunresectable metastatic/recurrent colorectal cancerJPRN-UMIN000024330Dept of Surgical Oncology Osaka City University Graduate School of Medicine35
招募中
2 期
Phase II study of combination chemotherapy with TS-1/irinotecan and bevacizumab as second-line therapy in patient with K-RAS mutation-type metastatic colorectal canceradvanced/metastatic colorectal cancerJPRN-UMIN000005900PO FMPC (Future Medicine Promoting Consortium)40
进行中（未招募）
1 期
Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutatioadult patients with AML and NPM1 mutationEUCTR2009-011889-28-ATniversity of Ulm588